期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

HBsAg定量对HBeAg阴性患者PEG-IFN治疗应答的预测 被引量：4

下载PDF
导出
摘要 目的评估HBsAg定量对HBeAg阴性患者聚乙二醇化干扰素α-2a(PEG-IFNα-2a)治疗应答的预测。方法HBeAg阴性慢性乙型肝炎患者采用PEG-IFNα-2a每次180ug,皮下注射,每周1次,治疗48周。Architect HBsAg定量检测系统测定治疗前、后12、24、48周时血清HBsAg定量,并分析血清HBsAg动态定量与治疗应答相关性。结果完成48周疗程65例,其中有46例(70.8%)在48周疗程结束时获得病毒学应答;随访24周,有25例(38.5%)患者获得持续病毒学应答(SVR);21例复发。获得SVR患者HBsAg基线水平低于非SVR患者(P<0.05)。治疗12、24周血清HBsAg水平及下降幅度差异有统计学意义(P<0.05)。治疗24周血清HBsAg定量水平<1500 IU/mL,下降幅度≥1 lgIU/mL的患者SVR率高(P<0.05)。结论采用PEG-IFNα-2a治疗的慢性乙型肝炎HBeAg阴性患者早期血清HBsAg下降对于获得SVR具有高度的预测价值,进行血清HBsAg定量检测有助于优化PEG-IFN的治疗方案。
作者 肖作汉 孟冈 王立志
机构地区 鄂州市中心医院感染病科
出处 《肝脏》 2014年第12期949-951,共3页 Chinese Hepatology
关键词 HBsAg 定量 聚乙二醇化干扰素Α-2A HBEAG 阴性 CHB
分类号 R512.62 [医药卫生—内科学]
  • 相关文献

参考文献11

  • 1朱雪娟,张欣欣.乙型肝炎病毒HBsAg定量检测的临床意义[J].中华肝脏病杂志,2011,19(8):637-640. 被引量：11
  • 2中会医学会肝病学分会,中华医学会感染病学分会,慢性乙型肝炎防治指南(2010年版).实用肝脏病杂志,2011,14:81-89.
  • 3余雪平,苏智军.血清乙型肝炎病毒表面抗原定量检测研究进展[J].中国实用内科杂志,2012,32(9):717-720. 被引量：4
  • 4Brunetto MR, Moriconi F, Bononi F, et al. HBsAg levels:a guide to sutained response HBeAg-Positive chronic hepatitis B using on- treat-ment HBsAg decline. Hepatology, 2010, 52: 1251-1257.
  • 5Moucari R, Mackiewiczv, Ladao, et al. Eary serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon difa-2a in HBeAg-negative patients. Hepatology, 2009, 43:1151-1157.
  • 6张欣欣,Stephen A.Locarnini.HBsAg定量检测在慢性乙型肝炎抗病毒治疗监测中的意义[J].中华检验医学杂志,2010,33(1):82-83. 被引量：17
  • 7Sonneveld MJ, Rijckborstv, Charles CA, et al. Prediction of sustained response to peginterferon difa-2b for to peginterferon dlfa-za in HBeAg-negative chronic hepatitis B. Hepatology, 2009, 49, 1141-1150.
  • 8谭淑燕,邹敏超,上官辉.HBsAg定量对聚乙二醇干扰素治疗HBeAg阴性慢性乙型肝炎疗效预测价值[J].海南医学,2013,24(19):2818-2820. 被引量：7
  • 9Thompson AJ, NguyenT, Iser D, et al. serum hepatitis B Surface antigen and hepatitis HBe antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B Virus markers. Hepatology, 2010, 51: 1933-1944.
  • 10Wiegand J, Wedemeyer H, Finger A, et al. A decline in hepatitis B Virus surface antigen (HBsAg) predicts clearance, but does not correlate with quantitative hbeag or HBV-DNA levels. Antivir Ther, 2008,13: 547-554.

二级参考文献88

  • 1European Association for the Study of the Liver. EASL Clinical Practice Guidelines : management of chronic hepatitis B. Gastroenterol Clin Biol, 2009, 33:539-554.
  • 2Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med, 2005, 352:2682-2695.
  • 3Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology, 2008, 48:750-758.
  • 4Gish RG, Lok AS, ChangTT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology, 2007, 133 : 1437-1444.
  • 5Heathcote E, Gane E J, deMan RA, et al. Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment and Adefovir Dipivoxil (ADV) Switch Data in HBeAg-Positive Patients With Chronic Hepatitis B ( Study 103 ) , Preliminary Analysis// 59th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco. 2008.
  • 6Gane E. The New Approach of Chronic Hepatitis B Research// 59th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, 2008.
  • 7Chang TT, Lai CL, Chien RN. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol, 2004, 19 : 1276-1282.
  • 8Yuen MF, Wong DK, Fung J, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology, 2008, 135:1192-1199.
  • 9Janssen HL,Kerhof-Los CJ, Heijtink RA, et al. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alphainterferon therapy. Antiviral research, 1994, 23:251-257.
  • 10Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology, 2004, 126 : 1750-1758.

共引文献40

同被引文献57

  • 1庄辉.乙型肝炎流行病学研究进展[J].中国医学前沿杂志（电子版）,2009,1(2):18-24. 被引量：90
  • 2Ying-Feng Wei,Guang-Ying Cui,Ping Ye,Jia-Ning Chen,Hong-Yan Diao.MicroRNAs may solve the mystery of chronic hepatitis B virus infection[J].World Journal of Gastroenterology,2013,19(30):4867-4876. 被引量：5
  • 3韩聚强,胡大荣,熊锦华,胡学玲,范公忍,李娟,刘超英,邸雅南,吴忆贫.C基因截短的HBV复制与包装[J].中华实验和临床病毒学杂志,2004,18(1):39-42. 被引量：2
  • 4秦来英,刘葵花,张照华,王耀宗.拉米夫定治疗期间患者血清乙型肝炎表面抗原定量的变化[J].中华肝脏病杂志,2005,13(8):602-602. 被引量：8
  • 5Ganem D, Prince AM. Hepatitis B virus infection natural history and clinical consequences. N Engl J Med, 2004, 350 : 1118-1129.
  • 6Stibbe W,Gerlich WH. Variable protein composition of hepatitis B surface antigen from different donors. Virology, 1982, 123 : 436- 442.
  • 7Sonneveld MJ, Rijckborst V, Boucher CA, et al. A comparison of two assays for quantification of Hepatitis B surface antigen in patients with chronic hepatitis B. J Clin Viroi, 2011, 51 : 175 -178.
  • 8Su TH, Hsu CS, Chen eL, et al. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir Ther, 2010, 15: 1133-1139.
  • 9Chan HL,Wong VW,Wong GL, et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology, 2010, 52: 1232-1241.
  • 10Thompson AJ,Nguyen T,lser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intra-hepatic hepatitis B virus markers. Hepatology, 2010, 51:1933 -944.

引证文献4

二级引证文献15

肝脏
2014年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部